Analysis of Ocular Excipients market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
According to the latest research by Fact.MR, Ocular Excipients market is set to experience steady growth during the year 2021-2031 at the CAGR of 7.3%. Smoothening of FDA approval processes has been crucial for this market as novel excipients with improved functionalities can be easily approved and used for better formulation without them being stuck in the legal web.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Excipients are important part of the drug development process and ensure that the formulation remains stable throughout the development process as well when it is administered. It is basically any other component of the drug outside the medicinal component as it acts as a vehicle or a carrier for the medicinal product.
This way stability to the formulation is provided. Wrong selection of excipient can lead to complications like intoxication of the patients. In ocular drugs, they play an important role in maintaining the tonicity, pH, stability, viscosity and sterility of the formulation.
Novel systems for drug delivery are being invented on a very large scale and this is driving the excipients market as certain advanced forms are required in order to put certain specific properties into the formulation. In this case, a single excipient can be required to perform various different functionalities so as to make the formulation versatile and novel. This factor will ultimately improve the overall performance of the drug which will finally lead to financial gains in the market.
Another major driver that emerges is that of new excipients and which will change the landscape of disease treatment is the characteristic of this component to prove effective in multiple ways in a formulation of drug where they can play different roles in ensuring the effectiveness of the drug which their earlier counterparts didn’t.
Pharmaceutical landscape is changing very rapidly as due to the emergence of new diseases, the research has gained pace. This in turn demands development of improved drugs; for which some of the previously used excipients might not be suitable. This has boosted the manufacturers in searching for new excipients which can be more suitable with their versatile capabilities.
The main issue with ocular drug delivery is its very poor bioavailability due to rapid wash out of the drug. This results in low permeation through the membranes.
A 15 April, 2021, study published in the International Journal of Pharmaceutics analysed muco-adhesiveness and permeation capability of a new excipient known as thiolated cyclodextrins. Improvement in permeation in the conjunctiva, sclera as well as cornea was seen. This also unlatches a new pathway into using thiolated cyclodextrins as an excipient in many more drug formulations in the future.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Ocular drug delivery has been mostly limited to injections and topical applications. The most widely used topical application has proven to be a convenient method despite of it failing to maintain an effective level of concentration of the drug at the target site for the ideal time period.
The 2021 review article from MDPI has collectively put up latest advances in the excipients market which have the potential in improving the bioavailability of ocular drugs. Chitosan, hyaluronic acid, poloxamers, and gelatin are few noteworthy that have displayed a promising potential in limiting the limitations presented by previous ocular delivery systems.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The healthcare system of the U.S. is well known for its advanced infrastructure and expenditure. Various regulatory rules and insurance policies are adopted to control the healthcare regime of the country. US doesn’t have a specific regulation when it comes to pharmaceutical excipients because as long as it fits the mechanisms of approval set by USFDA. This is sure to boost the acceptance of novel excipients in the US and make it the most lucrative market.
Europe is the second most major market in this field as efforts are being made by the International Pharmaceutical Excipients Commission with regards getting the necessary approvals and recognitions from the European Union with respect to the evolving excipient market.
At the IPEC Europe Excipient Forum of 2018, it was updated that excipients which have improved functionalities in comparison to the regular blends were not clearly defined in the European Union, despite of them being marketed as one for many years. It was then decided that a draft is to be sent to EU Commission with specific quality control measures required for these Co-processed excipients or CPEs for a review.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE: Although care has been taken to maintain the highest levels of accuracy in reports, recent market/vendor-specific changes may time to reflect in the analysis.
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesPre Book
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
- Related Reports -
The ocular excipients market is likely to record a CAGR of 7.3% during the forecast period.
The ocular excipients market has high growth potential due to the rise in drug development processes and changes in the landscape of disease treatment.
The manufacturers of the ocular excipients industry are likely to find the most opportunities in the U.S. and Canadian markets.
Need An Exclusive Report For Your Unique Requirement?